ONCY Stock Forecast & Price Target

Oncolytics Biotech is well positioned because its lead asset pelareorep is increasingly validated as an immune-priming platform, with randomized REO 033 in 2L RAS-mutated MSS mCRC now moving toward a registrational Part B after FDA feedback and an end-of-Phase meeting. The bull case is reinforced by REO 022’s strong signal—33% ORR, 16.6-month median PFS, 27.0-month median OS, and 19.5-month median duration of response—metrics that compare favorably with historical mCRC benchmarks and support a potential accelerated approval path. Despite a modest $4.1 million in cash and cash equivalents as of June 30, the company’s sharpened strategy, favorable patent runway to 2044 and potentially 2046, and partnership optionality across SCAC and mPDAC improve capital efficiency while preserving significant upside.

Oncolytics Biotech is viewed negatively because the GOBLET Cohort 4 readout has loosened with no date attached, removing a near-term catalyst that investors may have expected while also pushing SCAC pivotal initiation into a partner-gated process. Although the existing signal is encouraging, with 4 of 14 evaluable third-line patients responding for an approximately 29% ORR and a median duration of response of about 17 months, the company still faces substantial clinical execution risk across multiple tumor types and relies on an unproven asset in pelareorep. Financially, the model assumes annual gross equity raises of $50M-$100M from 2026E-2028E, implying dilution, while a reduction in terminal-year revenues and updated 2Q26 financials led to a lower valuation framework and reinforced a cautious outlook.